Ruzotolimod

1948241-60-8

Others|||SARS-CoV|||TLR|||HBV

Immunology/Inflammation|||Microbiology/Virology|||Others

Ruzotolimod, an agonist of TLR7, exhibits promising potential for investigating HBV, COVID-19, and SARS-CoV-2 infections (WO2021130195A1) [1].

O=C1N(C=2C(S1)=CN=C(N)N2)[C@@H]3O[C@]([C@@H](OC(C)=O)CC)(C[C@H]3O)[H]

C14H18N4O5S

354.38

Cool pack

-20°C